Focusing on Personalized Medicine, Pfizer Reports PGx Data for Several Oncologics at ASCO

The slew of PGx abstracts presented by the drug giant at the annual oncology meeting highlighted its “focused approach to cancer drug development through the identification and validation of molecular targets,” Pfizer said.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.